Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide vs mesalazine in active ulcerative colitis (phase III)
2006-005377-22Phase 3Terminated
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Jul 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Budesonide arm with Mesalazine arm (2 arms). Primary endpoint: Clinical remission at week 8 (LOCF). Started Jul 2007; status: terminated.
02
Drugs
budesonideSalcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2006-005377-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005377-22.